Tutykhina I et al.Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts.PLoS One 13:e0191574 (2018).
Opriessnig T et al.Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model.PLoS One 13:e0191739 (2018).
Spronken MI et al.A compensatory mutagenesis study of a conserved hairpin in the M gene segment of influenza A virus shows its role in virus replication.RNA Biol 14:1606-1616 (2017).
Zhu P et al.Host Cellular Protein TRAPPC6A? Interacts with Influenza A Virus M2 Protein and Regulates Viral Propagation by Modulating M2 Trafficking.J Virol 91:N/A (2017).
Turnbull ML et al.Role of the B Allele of Influenza A Virus Segment 8 in Setting Mammalian Host Range and Pathogenicity.J Virol 90:9263-84 (2016).
Nogales A et al.Rearrangement of Influenza Virus Spliced Segments for the Development of Live-Attenuated Vaccines.J Virol 90:6291-302 (2016).
Khaperskyy DA et al.Selective Degradation of Host RNA Polymerase II Transcripts by Influenza A Virus PA-X Host Shutoff Protein.PLoS Pathog 12:e1005427 (2016).
Gaunt E et al.Elevation of CpG frequencies in influenza A genome attenuates pathogenicity but enhances host response to infection.Elife 5:e12735 (2016).
Stepanova LA et al.Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.PLoS One 10:e0119520 (2015).
Zheng M et al.An A14U Substitution in the 3' Noncoding Region of the M Segment of Viral RNA Supports Replication of Influenza Virus with an NS1 Deletion by Modulating Alternative Splicing of M Segment mRNAs.J Virol 89:10273-85 (2015).
Ohtsuka J et al.Vero/BC-F: an efficient packaging cell line stably expressing F protein to generate single round-infectious human parainfluenza virus type 2 vector.Gene Ther N/A:N/A (2014).
Sawaengsak C et al.Intranasal chitosan-DNA vaccines that protect across influenza virus subtypes.Int J Pharm 473:113-25 (2014).
Wang L et al.Nanoclusters self-assembled from conformation-stabilized influenza M2e as broadly cross-protective influenza vaccines.Nanomedicine N/A:N/A (2013).
He J et al.Dual function of CD81 in influenza virus uncoating and budding.PLoS Pathog 9:e1003701 (2013).
Amorim MJ et al.Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection.J Virol 87:4694-703 (2013).
Sun E et al.Dissecting the role of COPI complexes in influenza virus infection.J Virol 87:2673-85 (2013).
Seo YJ et al.Sphingosine kinase 1 serves as a pro-viral factor by regulating viral RNA synthesis and nuclear export of viral ribonucleoprotein complex upon influenza virus infection.PLoS One 8:e75005 (2013).
Ma X et al.Enhancing lysosome biogenesis attenuates BNIP3-induced cardiomyocyte death.Autophagy 8: (2012).
Wu CY et al.A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.PLoS One 7:e42363 (2012).
Amorim MJ et al.A rab11- and microtubule-dependent mechanism for cytoplasmic transport of influenza a virus viral RNA.J Virol 85:4143-56 (2011).
Song JM et al.Influenza virus-like particles containing m2 induce broadly cross protective immunity.PLoS One 6:e14538 (2011).
Wu CY et al.Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus.PLoS One 5:e9784 (2010).
Read EK & Digard P Individual influenza A virus mRNAs show differential dependence on cellular NXF1/TAP for their nuclear export.J Gen Virol 91:1290-301 (2010).
Noton SL et al.Studies of an influenza A virus temperature-sensitive mutant identify a late role for NP in the formation of infectious virions.J Virol 83:562-71 (2009).
Brass AL et al.The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.Cell 139:1243-54 (2009).
Beerli RR et al.Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.Virol J 6:224 (2009).
Wang R et al.Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein.Antiviral Res 80:168-77 (2008).
Hutchinson EC et al.Mutational analysis of cis-acting RNA signals in segment 7 of influenza A virus.J Virol 82:11869-79 (2008).
Amorim MJ et al.Nuclear export of influenza A virus mRNAs requires ongoing RNA polymerase II activity.Traffic 8:1-11 (2007).